OP0114CHANNELING BIAS AND ADVERSE EVENTS IN RA PATIENTS TREATED WITH B/TSDMARDS DO NEW DRUGS APPEAR MORE DANGEROUS THE FIRST YEARS AFTER MARKET ENTRY?

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: V. Molander, H. Bower, T. Frisell, J. Askling

Journal title: Scientific Abstracts

Journal publisher: BMJ Publishing Group Ltd and European League Against Rheumatism

Published year: 2024

DOI identifier: 10.1136/annrheumdis-2024-eular.235